Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Immunomodulatory treatment trial for paraneoplastic neurological disorders.

Vernino S, O'Neill BP, Marks RS, O'Fallon JR, Kimmel DW.

Neuro Oncol. 2004 Jan;6(1):55-62.

2.

[Evaluation of the long term effect of mitoxantrone on neurological disability in patients with active multiple sclerosis].

Mesaros S, Stojsavljević N, Dujmović I, Mandić E, Drulović J.

Srp Arh Celok Lek. 2004 Jul-Aug;132(7-8):209-13. Serbian.

4.
5.

Paraneoplastic neurological syndromes - patients' cohort profile in the Czech Republic.

Stourac P, Kadanka Z, Palyza V.

Acta Neurol Scand. 2001 Aug;104(2):72-7.

PMID:
11493221
6.

Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy.

Niermeijer JM, Eurelings M, van der Linden MW, Lokhorst HM, Franssen H, Fischer K, Teunissen LL, van den Berg LH, Schobben F, Wokke JH, Notermans NC.

Neurology. 2007 Jul 3;69(1):50-9.

PMID:
17606880
7.

FOOD: a multicentre randomised trial evaluating feeding policies in patients admitted to hospital with a recent stroke.

Dennis M, Lewis S, Cranswick G, Forbes J; FOOD Trial Collaboration.

Health Technol Assess. 2006 Jan;10(2):iii-iv, ix-x, 1-120.

8.

Functional outcomes in first-episode patients with bipolar disorder: a prospective study from the Systematic Treatment Optimization Program for Early Mania project.

Kauer-Sant'Anna M, Bond DJ, Lam RW, Yatham LN.

Compr Psychiatry. 2009 Jan-Feb;50(1):1-8. doi: 10.1016/j.comppsych.2008.05.013. Epub 2008 Aug 23.

PMID:
19059506
9.

Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris.

Olszewska M, Kolacinska-Strasz Z, Sulej J, Labecka H, Cwikla J, Natorska U, Blaszczyk M.

Am J Clin Dermatol. 2007;8(2):85-92.

PMID:
17428113
10.

Effects of intraoperative hypothermia on neuropsychological outcomes after intracranial aneurysm surgery.

Anderson SW, Todd MM, Hindman BJ, Clarke WR, Torner JC, Tranel D, Yoo B, Weeks J, Manzel KW, Samra S; IHAST Investigators.

Ann Neurol. 2006 Nov;60(5):518-27.

11.
12.

The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft for posterolateral lumbar arthrodesis: minimum 4-year follow-up of a pilot study.

Vaccaro AR, Whang PG, Patel T, Phillips FM, Anderson DG, Albert TJ, Hilibrand AS, Brower RS, Kurd MF, Appannagari A, Patel M, Fischgrund JS.

Spine J. 2008 May-Jun;8(3):457-65. Epub 2007 May 25.

PMID:
17588821
13.

[Treatment of progressive multiple sclerosis with monthly pulsed cyclophosphamide-methylprednisolone: predictive factors of treatment response].

Delmont E, Chanalet S, Bourg V, Soriani MH, Chatel M, Lebrun C.

Rev Neurol (Paris). 2004 Jul;160(6-7):659-65. French.

PMID:
15247854
14.

Voice and swallowing outcomes of an organ-preservation trial for advanced laryngeal cancer.

Fung K, Lyden TH, Lee J, Urba SG, Worden F, Eisbruch A, Tsien C, Bradford CR, Chepeha DB, Hogikyan ND, Prince ME, Teknos TN, Wolf GT.

Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1395-9. Epub 2005 Aug 8.

PMID:
16087298
15.

How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial.

Matteson EL, Weyand CM, Fulbright JW, Christianson TJ, McClelland RL, Goronzy JJ.

Rheumatology (Oxford). 2004 May;43(5):619-25. Epub 2004 Feb 24. Erratum in: Rheumatology (Oxford). 2004 Aug;43(8):1065.

PMID:
14983105
16.

Managing paraneoplastic neurological disorders.

de Beukelaar JW, Sillevis Smitt PA.

Oncologist. 2006 Mar;11(3):292-305. Review.

17.

Immunotherapy for paraneoplastic neurological disorders.

Dropcho EJ.

Expert Opin Biol Ther. 2005 Oct;5(10):1339-48. Review.

PMID:
16197339
18.

Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience.

Villa-Forte A, Clark TM, Gomes M, Carey J, Mascha E, Karafa MT, Roberson G, Langford CA, Hoffman GS.

Medicine (Baltimore). 2007 Sep;86(5):269-77.

19.

A prospective open-label study of sirolimus for the treatment of anti-Hu associated paraneoplastic neurological syndromes.

de Jongste AH, van Gelder T, Bromberg JE, de Graaf MT, Gratama JW, Schreurs MW, Hooijkaas H, Sillevis Smitt PA.

Neuro Oncol. 2015 Jan;17(1):145-50. doi: 10.1093/neuonc/nou126. Epub 2014 Jul 3.

20.

[Classic paraneoplastic syndromes: diagnostic and treatment approach].

Gállego Pérez-Larraya J, Dalmau J.

Neurologia. 2008 Sep;23(7):441-8. Spanish.

PMID:
18726722

Supplemental Content

Support Center